Home > Dermatology > EADV 2020 > JAK Inhibitors – A Fascinating Novel Drug Class > JAK1 inhibition successful in hidradenitis suppurativa

JAK1 inhibition successful in hidradenitis suppurativa

Presented By
Dr Afsaneh Alavi , Mayo Clinic, USA
Conference
EADV 2020
Trial
Phase 2
The results of two phase 2 trials with a novel Janus kinase (JAK) 1 inhibitor showed a good safety profile in patients with moderate-to-severe hidradenitis suppurativa (HS). Patient with HS experience painful inflammatory lesions and have a markedly reduced quality of life. The rationale for using a JAK inhibitor in this indication is that treatments targeting pro-inflammatory cytokine signalling may influence disease pathology and ameliorate symptoms of HS. “There is an unmet medical need for an oral treatment for these patients,” said Dr Afsaneh Alavi (Mayo Clinic, USA) during the presentation of the results from two phase 2 studies with the JAK1 inhibitor INCB054707 [1]. INCB054707 is an oral, small-molecule, JAK1 inhibitor with 52-fold greater selectivity for JAK1 versus JAK2. Study 1 was an open-label, single-arm study (NCT03569371), and stud...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on